SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX ), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024 , after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.
m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan , Chief Executive Officer, Brian Brown , Chief Financial Officer, and Andrew Benson , Head of Investor Relations.
The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international) If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease. SOURCE Co-Diagnostics.
